BioPharmSignal logoBioPharmSignal

Biotech News

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

PTC Therapeutics, Inc. (PTCT)PTC Therapeutics, Inc.Earnings

WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial results and provide a business update on Thursday, Oct. 29, 2026, at 4:30 p.m. ET.

Related news

PTCTPTC Therapeutics, Inc.2026-07-16 12:00 EST

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

PTCTPTC Therapeutics, Inc.2026-07-30 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

CAPRCapricor Therapeutics2026-08-10 12:30 EST

Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13

CAPRCapricor Therapeutics2026-08-13 20:05 EST

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MNPRMonopar2026-08-12 13:30 EST

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

TARAProtara Therapeutics2026-08-11 12:00 EST

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ETONEton Pharmaceuticals2026-08-03 10:50 EST

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

BCRXBioCryst Pharmaceuticals2026-10-21 20:01 EST

BioCryst to Report Third Quarter 2026 Financial Results on November 4

AGIOAgios Pharmaceuticals, Inc.2026-10-08 11:00 EST

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

View all latest news

PTC Therapeutics, Inc.

Rare-Disease Medicines PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders. Its portfolio spans metabolic, neurologic and neuromuscular diseases. Commercial Portfolio Sephience, or sepiapterin, is a therapy for phenylketonuria and represents a growing global commercial franchise....

Recent company news

PTCTPTC Therapeutics, Inc.2026-10-15 12:00 EST

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

PTCTPTC Therapeutics, Inc.2026-09-25 20:30 EST

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTCTPTC Therapeutics, Inc.2026-09-21 20:30 EST

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

PTCTPTC Therapeutics, Inc.2026-08-27 12:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTCTPTC Therapeutics, Inc.2026-08-24 12:00 EST

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

Stock data

Close
62.62 USD
Market cap
5.66B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States